TOPIC SERIES: CVD PREVENTION IN RHEUMATIC DISEASE

HealthDay News – The U.S. Preventive Services Task Force (USPSTF) updated its guidelines on the use of low-dose aspirin for the prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults.  The USPTF now recommends that adults aged 50 to 69 years with a 10% or greater 10-year risk of CVD, and who do not have an elevated bleeding risk, take low-dose (≤100 mg/day)  aspirin daily. These recommendations were published in the Annals of Internal Medicine.

Albert L. Siu, MD, MSPH, from the USPSTF, and colleagues reviewed the literature to update the 2009 recommendations relating to the combined benefits and harms of taking aspirin for primary prevention of both CVD events and CRC.


Continue Reading

The researchers recommend low-dose aspirin for adults aged 50 to 59 years with a ≥10 percent 10-year CVD risk, without elevated bleeding risk, who have a ≥10 year life expectancy, and who are prepared to take aspirin daily for ≥10 years (B recommendation). For adults aged 60 to 69 years, the decision to initiate aspirin for primary prevention should be an individual one (C recommendation).

The current evidence is insufficient to weigh the balance of benefits and harms of aspirin for primary prevention of CVD and CRC in adults aged younger than 50 years and age 70 years or older (I statements)

Summary and Clinical Applicability

The USPSTF updated its guidelines from 2009 on the use of prophylactic low-dose aspirin for the prevention of CVD and CRC in adults. They recommend that adults aged 50 to 69 years with a 10% or greater 10-year risk of CVD, life expectancy of at least 10 years, and do not have an elevated bleeding risk take low-dose (≤100 mg/day)  aspirin daily.

“Before starting to take aspirin for primary prevention, people aged 50 to 69 should talk to their primary care clinician to understand their risk of cardiovascular disease and risk for bleeding,” USPSTF chair Kirsten Bibbins-Domingo, PhD, MD, said in a statement.

Limitations and Disclosures

The following statement accompanied the article:

“[The U.S. Preventive Taske Force (USPSTF)] bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation.”

Reference 

Bibbins-domingo K. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;  Published online April 12, 2016 doi:10.7326/M16-0577